Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay

Objective: This study aimed to determine the diagnostic efficiency of a novel immunoblotting detection assay for anti-ganglioside antibodies (AGAs) in the Guillain–Barre syndrome (GBS).Method: Serum immunoglobulin (IgG and IgM) of AGAs were measured in 121 participants from a registered cohort study of immune-mediated neuropathies and 29 healthy controls by immunoblotting panel assay. Sensitivity, specificity, and positive predictive value (PPV) of the assay were compared to calculate the diagnostic accuracy.Result: In our cohort, any of the AGAs were positive in 42.4% of the GBS patients. The sensitivity and specificity of AGAs (both IgG and IgM) in the diagnosis of GSB were 42 and 76% while for IgG-AGAs were 35 and 87%. AGAs positivity had a significant association with the AMAN subtype (P = 0.0004), and the sensitivity, specificity of AGAs in AMAN were 86, 69%, respectively with high (AUC = 0.78, p = 0.002) discriminative powers. GM1-IgG AGA was more common and specific to AMAN patients than other GBS forms (p = 0.008).Conclusion: Our novel immunoblotting detection assay could complement GBS diagnosis. IgG-AGAs were more likely to be detected in GBS, and GM1-IgG AGA could assist AMAN diagnosis.

Download Full-text

Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain–Barré syndrome

Journal of Neuroimmunology ◽

10.1016/j.jneuroim.2004.12.001 ◽

2005 ◽

Vol 161 (1-2) ◽

pp. 183-189 ◽

Cited By ~ 27

Author(s):

Karin Geleijns ◽

Jon D. Laman ◽

Wouter van Rijs ◽

Anne P. Tio-Gillen ◽

Rogier Q. Hintzen ◽

...

Keyword(s):

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Ganglioside Antibodies ◽

Guillain Barré

Download Full-text

Study of Guillain-Barre syndrome etiology in Pakistani patients

Journal of the Pakistan Medical Association ◽

10.47391/jpma.202 ◽

2021 ◽

Author(s):

Rashid Iqbal ◽

Muhammad Javaid Asad ◽

Saima Siddiqi ◽

Raja Tahir Mahmood ◽

Muhamamd Baseer Shah ◽

...

Keyword(s):

Cerebrospinal Fluid ◽

Nerve Conduction ◽

Treatment Strategies ◽

Guillain Barre Syndrome ◽

Clinical Feature ◽

Interleukin 17 ◽

Healthy Controls ◽

Female Ratio ◽

Guillain Barré Syndrome ◽

Guillain Barré

Objective: To examine clinical features, biochemical markers, demographic features, antecedent infections, frequency and treatment strategies. Methods: This case-control study was conducted at Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan and District Headquarters Hospital (DHQ), Rawalpindi, Pakistan from 2018 to 2020. Ninety consecutive patients of Guillain-Barré syndrome (GBS) and 77 healthy controls were enrolled. Patients were diagnosed by clinical presentation, Nerve conduction study (NCS), Electromyography (EMG), Cerebrospinal fluid analysis (CSF) and biochemical profile. Data was analyzed on IBM SPSS version 23. Results: Symmetrical ascending weakness was the striking clinical feature. Mean age was 40.20±14.90 years and male to female ratio was 2.1:1. Acute inflammatory demyelinating polyneuropathy (AIDP) was found to be the most common electrophysiological variant of GBS (46%). There was considerable difference in Interleukin-17(IL-17) levels between GBS patients 23.12 ± 3.41 pg/ml and healthy controls 8.82 ± 2.49. Mean IL-17 level was markedly increased in GBS patients, P=0.006, P<0.05. Gastrointestinal infection was the most common preceding infection (56.66%). Mean CSF protein was 100.83 g/dl with ± 51.32 standard deviation and albumio cytologic dissociation (ACD) was different in all four variants of GBS, P= 0.005. Conclusion: GBS was presented by all ages. Males were more affected than females. About two third of GBS patients showed an antecedent infection before GBS onset. Increased levels of cytokine (IL-17) showed involvement of autoimmunity. ACD differentiated it from poliomyelitis. Plasmapheresis and intravenous immunoglobulin (IVIG) therapy were used to treat patients. Key words: Guillain-Barré Syndrome; cerebrospinal fluid; albuminocytologic dissociation; nerve conduction studies; variants; electromyography Continuous....

Download Full-text

Reworsening of Recurrent Guillain-Barré Syndrome Triggered by COVID-19 Infection

The Open Neurology Journal ◽

10.2174/1874205x02115010048 ◽

2021 ◽

Vol 15 (1) ◽

pp. 48-51

Author(s):

Gian Luca Vita ◽

Carmen Terranova ◽

Maria Sframeli ◽

Antonio Toscano ◽

Giuseppe Vita

Keyword(s):

Viral Infection ◽

Neurological Diseases ◽

Intravenous Immunoglobulins ◽

Guillain Barre Syndrome ◽

Case Presentation ◽

Appropriate Treatment ◽

Immune Mediated ◽

Guillain Barré Syndrome ◽

Guillain Barré

Introduction: Guillain-Barré Syndrome (GBS) is an acute, immune-mediated, generalized polyradiculoneuropathy often triggered by a bacterial or viral infection, vaccination, or surgery. During the SARS-CoV-2 pandemic, some patients were reported with GBS associated COVID-19 infection. Case Presentation: We report, herein, a patient who had a recurrent GBS after forty years. Intravenous immunoglobulins (IVIg) induced improvement, but her condition worsened suddenly after twenty days, coinciding with a COVID-19 infection. A second IVIg cycle was administered, and she improved again. Conclusion: The take-home message is that in the current pandemic, any re-worsening or lack of improvement after appropriate treatment of GBS or possibly other autoimmune neurological diseases must be checked to determine if it is related to COVID-19 infection.

Download Full-text

Colistin neurotoxicity mimicking Guillain-Barré syndrome in a patient with cystic fibrosis: case report and review

Oxford Medical Case Reports ◽

10.1093/omcr/omab080 ◽

2021 ◽

Vol 2021 (9) ◽

Author(s):

Celeste Camargo ◽

Tathagat Narula ◽

Daniel A Jackson ◽

Teresa Padro ◽

W David Freeman

Keyword(s):

Cystic Fibrosis ◽

Drug Toxicity ◽

Clinical Presentation ◽

Guillain Barre Syndrome ◽

Drug Induced ◽

Common Presentation ◽

Intravenous Treatment ◽

Immune Mediated ◽

Guillain Barré Syndrome ◽

Guillain Barré

ABSTRACT Guillain-Barré syndrome (GBS) is an immune-mediated polyneuropathy, which is characterized by areflexia and ascending paresthesia which can progress to a respiratory failure. Certain conditions, such as vasculitis and heavy metal and drug toxicity, may have misleadingly similar clinical presentation to GBS. We describe a case of a patient with cystic fibrosis and intravenous colistin-induced neurotoxicity mimicking GBS. The patient had used inhaled colistin on five occasions with no adverse effects, however, developed symptoms on the second day of intravenous treatment. Overlapping findings between immune-mediated polyneuropathy and drug-induced neurotoxicity include limb paresthesia and decreased reflexes. Perioral tingling, however, is a common presentation of colistin-induced neurotoxicity, and therefore, is an important differentiating factor. Early diagnosis prevents further neurologic decline, extensive unnecessary workup and potentially harmful incorrect management.

Download Full-text

Recurrent Guillain-Barré Syndrome with Anti-GT1a and Anti-GQ1b Ganglioside Antibodies

Journal of Clinical Neurology ◽

10.3988/jcn.2019.15.3.404 ◽

2019 ◽

Vol 15 (3) ◽

pp. 404

Author(s):

Jihyeon Hwang ◽

Ye-Ji Kwon ◽

Jong Kuk Kim ◽

Nam Jun Kim ◽

Seol-Hee Baek

Keyword(s):

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Ganglioside Antibodies ◽

Guillain Barré ◽

Gq1b Ganglioside

Download Full-text

Patients’ experiences and perceptions of Guillain-Barré syndrome: A systematic review and meta-synthesis of qualitative research

PLoS ONE ◽

10.1371/journal.pone.0245826 ◽

2021 ◽

Vol 16 (2) ◽

pp. e0245826

Author(s):

Despina Laparidou ◽

Ffion Curtis ◽

Joseph Akanuwe ◽

Jennifer Jackson ◽

Timothy L. Hodgson ◽

...

Keyword(s):

Systematic Review ◽

Guillain Barre Syndrome ◽

Link Type ◽

Immune Mediated ◽

Acceptable Quality ◽

Guillain Barré Syndrome ◽

Internet Searches ◽

Guillain Barré ◽

Full Text Screening

Background Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy, with an incidence of 1-2/100,000 per year. Its severity is variable, ranging from very mild cases with brief weakness to severe paralysis, leading to inability to breathe independently, or even death. Currently there is limited evidence exploring the experiences of GBS patients. The aim of this study was to review patients’ experiences and perceptions of GBS and its variants at diagnosis, discharge and during recovery, by conducting a systematic review and thematic meta-synthesis of qualitative studies of patients’ experiences of GBS (and its variants). Methods We searched twelve electronic databases, supplemented with internet searches and forward and backward citation tracking from the included studies and review articles. Data were synthesised thematically following the Thomas and Harden approach. The CASP Qualitative Checklist was used to assess the quality of the included studies of this review. Results Our search strategy identified a total of 5,282 citations and after removing duplicates and excluding citations based on title and abstract, and full-text screening, five studies were included in the review and meta-synthesis; all included studies were considered of acceptable quality. Through constant discussions and an iterative approach, we developed six analytical themes following a patient’s journey from suspecting that they had a health problem, through to being hospitalised, experiencing ongoing difficulties, slowly recovering from GBS, adjusting to their new circumstances, and re-evaluating their lives. Conclusions Despite the variety of experiences, it was evident from all included studies that being diagnosed with and surviving GBS was a life-changing experience for all participants. Trial registration Protocol was registered (CRD42019122199) on the International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO).

Download Full-text